| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 27,658 | 30,292 | ||
| Accounts receivable, net | 59,639 | 55,659 | ||
| Other receivables | 339 | 276 | ||
| Inventories | 18,882 | 15,786 | ||
| Prepaid expenses and other current assets | 3,574 | 2,779 | ||
| Total current assets | 110,092 | 104,792 | ||
| Property and equipment, net | 10,714 | 10,854 | ||
| Operating right of use assets | 23,265 | 23,887 | ||
| Intangible assets, net | 11,732 | 12,449 | ||
| Goodwill | 7,230 | 7,230 | ||
| Other assets | 586 | 586 | ||
| Total assets | 163,619 | 159,798 | ||
| Accounts payable | 35,634 | 34,933 | ||
| Current portion of operating lease liabilities | 7,161 | 6,953 | ||
| Accrued expenses and other current liabilities | 22,785 | 22,892 | ||
| Total current liabilities | 65,580 | 64,778 | ||
| Operating lease liabilities | 20,195 | 21,179 | ||
| Derivative warrant liabilities | 262 | 112 | ||
| Conversion option derivative liabilities | 13,658 | 7,681 | ||
| Long-term debt, net of unamortized debt issuance costs | 76,195 | 75,023 | ||
| Other non-current liabilities | 3 | 10 | ||
| Deferred income taxes liability | 0 | 0 | ||
| Total liabilities | 175,893 | 168,783 | ||
| Common stock, 0.0001 par value, authorized 500,000,000 shares 99,303,511 shares issued and 97,569,737 shares outstanding at september30, 2025 and 77,470,886 shares issued and 75,737,112 shares outstanding at december31, 2024 | 10 | 9 | ||
| Additional paid-in capital | 252,646 | 239,432 | ||
| Treasury stock at cost, 1,733,774 shares at september30, 2025 and december31, 2024 | 1,019 | 1,019 | ||
| Accumulated deficit | -263,911 | -247,407 | ||
| Total stockholders equity (deficit) | -12,274 | -8,985 | ||
| Total liabilities and stockholders equity (deficit) | 163,619 | 159,798 | ||
Oncology Institute, Inc. (TOIIW)
Oncology Institute, Inc. (TOIIW)